<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>SENâ€‘B Project</title>
  <style>
    /* Base layout */
    body{margin:0;font-family:Arial,Helvetica,sans-serif;color:#333;background:#fdfdfd;line-height:1.6}
    header{background:#2c3e50;color:#fff;padding:1rem 0}
    .container{max-width:1200px;margin:0 auto;padding:0 1rem}
    nav ul{list-style:none;display:flex;gap:1rem;padding:0;margin:0}
    nav a{color:#fff;text-decoration:none;font-weight:bold}
    nav a:hover{opacity:.8}
    section{padding:2rem 0}

    /* Sections initially hidden except Home */
    #senb,#hep,#contact{display:none}

    /* Make the content area fullâ€‘width so the hero can stretch edgeâ€‘toâ€‘edge */
    main.container{max-width:none;padding:0}

    /* Hero styles */
    #home{padding:0;margin:0}
    .hero{width:100%;margin:0;position:relative}
    .hero img{display:block;width:100%;height:70vh;max-width:none;object-fit:cover;border-radius:0;box-shadow:none}
    /* Caption anchored flush at the bottom of the hero so it is always visible */
    .hero-caption{position:absolute;bottom:0;left:0;width:100%;background:rgba(44,62,80,.75);color:#fff;padding:1rem 1.5rem;text-align:center}
    .hero-caption h2{margin:0 0 .5rem 0;color:#fff}
    .hero-caption p{margin:0;font-size:1rem;color:#f0f0f0}

    /* Typography & colours */
    h2{color:#2c3e50;margin-top:0}
    h3{color:#0066a1;margin-top:1.2rem}

    footer{background:#2c3e50;color:#fff;text-align:center;padding:1rem;margin-top:2rem}

    /* Chatbot styles */
    .chat-btn{position:fixed;bottom:20px;right:20px;width:56px;height:56px;border:none;border-radius:50%;background:#0066a1;color:#fff;font-size:24px;cursor:pointer;box-shadow:0 2px 6px rgba(0,0,0,.3);z-index:1000}
    .chat-window{position:fixed;bottom:90px;right:20px;width:300px;max-height:400px;background:#fff;border-radius:8px;box-shadow:0 4px 8px rgba(0,0,0,.2);display:none;flex-direction:column;overflow:hidden;z-index:1000}
    .chat-header{background:#0066a1;color:#fff;padding:0.5rem;text-align:center;font-weight:bold}
    .chat-messages{flex:1;padding:0.5rem;overflow-y:auto;font-size:0.9rem}
    .chat-messages div{margin-bottom:0.5rem}
    .chat-input{display:flex;border-top:1px solid #ddd}
    .chat-input input{flex:1;border:none;padding:0.5rem;font-size:0.9rem}
    .chat-input button{border:none;background:#0066a1;color:#fff;padding:0.5rem 1rem;cursor:pointer}
  </style>
  <script>
    /* Navigation */
    function showSection(id){
      document.querySelectorAll('main section').forEach(s=>s.style.display='none');
      document.getElementById(id).style.display='block';
      window.scrollTo({top:0,behavior:'smooth'});
    }

    /* Simple FAQâ€‘based chatbot */
    const faqs=[
      {q:/\bwhat is hepatitis b\b/i,a:"Hepatitis B is a viral infection that attacks the liver and can cause acute and chronic disease."},
      {q:/\btransmit|spread|transmission/i,a:"HBV is commonly transmitted at birth, through contact with infected blood or body fluids, unprotected sex, or sharing needles."},
      {q:/\bvaccin|vaccine/i,a:"Yes. A safe and effective vaccine has been available since 1982 and is administered at birth with booster doses."},
      {q:/\bsen-?b project/i,a:"The SENâ€‘B project follows nearly 1,000 adults in Dakar to study HBV treatment outcomes and prevention strategies."},
      {q:/\bcoordinator|contact/i,a:"Key contacts: Prof. GillesÂ Wandeler, Prof. MoussaÂ Seydi, Dr. AdriÃ Â RamirezÂ Mena and Ms. BintouÂ Fall."},
      {q:/\bparticipate|enrol|join/i,a:"If you're interested in participating, please reach out to the Infectious and Tropical Diseases Unit (SMIT) at CHNUâ€¯Fann."}
    ];

    function toggleChat(){
      const win=document.getElementById('chatWin');
      if(!win) return; // safety guard
      win.style.display=win.style.display==='flex'? 'none':'flex';
    }
    function sendChat(){
      const input=document.getElementById('chatInput');
      const msg=input.value.trim();
      if(!msg) return;
      addMessage('You',msg);
      let response="Sorry, I don't have an answer yet. Please contact the SENâ€‘B team.";
      for(const f of faqs){if(f.q.test(msg)){response=f.a;break;}}
      addMessage('Bot',response);
      input.value='';
    }
    function addMessage(sender,text){
      const box=document.getElementById('chatMsgs');
      const div=document.createElement('div');
      div.innerHTML='<strong>'+sender+':</strong> '+text;
      box.appendChild(div);
      box.scrollTop=box.scrollHeight;
    }
    document.addEventListener('DOMContentLoaded',()=>{
      showSection('home');
      document.getElementById('chatInput')?.addEventListener('keypress',e=>{if(e.key==='Enter')sendChat();});
    });
  </script>
</head>
<body>
  <header>
    <div class="container" style="display:flex;align-items:center;gap:0.5rem;flex-wrap:wrap">
      <img src="https://upload.wikimedia.org/wikipedia/commons/f/fd/Flag_of_Senegal.svg" alt="Flag of Senegal" style="height:24px;border-radius:2px;box-shadow:0 2px 4px rgba(0,0,0,.2)">
      <h1 style="margin:0;font-size:1.5rem">SENâ€‘B Project</h1>
      <nav style="margin-left:auto">
        <ul>
          <li><a href="#" onclick="showSection('home');return false;">Home</a></li>
          <li><a href="#" onclick="showSection('senb');return false;">About SENâ€‘B Project</a></li>
          <li><a href="#" onclick="showSection('hep');return false;">About HepatitisÂ B</a></li>
          <li><a href="#" onclick="showSection('contact');return false;">Contact</a></li>
        </ul>
      </nav>
    </div>
  </header>

  <main class="container">
    <!-- Home / Landing -->
    <section id="home">
      <div class="hero">
        <img src="https://raw.githubusercontent.com/BinouB/graph_final_project/main/real_istock-1439770412-foie-1668424706.jpg" alt="Hepatitis B virus attacking the liver">
        <div class="hero-caption">
          <h2>Welcome</h2>
          <p>Discover our commitment to tackling hepatitisÂ B in Senegal through the SENâ€‘B cohort study.</p>
        </div>
      </div>
    </section>

    <!-- About SEN-B Project -->
    <section id="senb">
      <div class="container" style="max-width:800px">
        <h2>About the SENâ€‘B Project</h2>
        <p>The SENâ€‘B project follows a cohort of nearly 1,000 adult patients with HBV monoinfection or HIV/HBV coinfection at the Infectious and Tropical Diseases Unit (SMIT) of Fann University Hospital (CHNU) in Dakar, Senegal.</p>
        <h3>Specific Objectives</h3>
        <ul>
          <li>Evaluate eligibility for HBV antiviral treatment and monitor clinical and virological responses.</li>
          <li>Determine hepatocellular carcinoma (HCC) incidence and develop a predictive score to guide screening.</li>
          <li>Investigate intraâ€‘hepatic histopathological determinants and validate peripheral cccDNA biomarkers.</li>
          <li>Assess knowledge and perceptions of HBV treatment through a socioâ€‘anthropological study.</li>
          <li>Monitor SARSâ€‘CoVâ€‘2 seroprevalence trends among people living with HBV in the cohort.</li>
        </ul>
      </div>
    </section>

    <!-- About Hepatitis B -->
    <section id="hep">
      <div class="container" style="max-width:800px">
        <h2>About HepatitisÂ B</h2>
        <h3>Key Facts</h3>
        <ul>
          <li>HepatitisÂ B is a viral infection that attacks the liver and can cause both acute and chronic disease.</li>
          <li>The virus is most commonly transmitted from mother to child at birth, in early childhood, or through contact with blood or other body fluids during unprotected sex, unsafe injections, or exposure to sharp instruments.</li>
          <li>In 2022, an estimated 254Â million people were living with chronic hepatitisÂ B, with 1.2Â million new infections each year.</li>
          <li>Approximately 1.1Â million deaths occurred in 2022, mainly from cirrhosis or hepatocellular carcinoma.</li>
          <li>Safe and effective vaccines are available to prevent hepatitisÂ B.</li>
        </ul>

        <h3>Overview</h3>
        <p>HepatitisÂ B is a liver infection caused by the hepatitisÂ B virus (HBV). The infection can be acute (shortâ€‘term) or chronic (longâ€‘term) and can lead to cirrhosis or liver cancer. The virus spreads through contact with infected body fluids (blood, saliva, vaginal secretions, semen) and from mother to infant at birth. Vaccination shortly after birth, followed by booster doses, provides nearâ€‘complete protection. The Western Pacific and African regions bear the highest burden, with millions of chronic infections worldwide.</p>
        <ul>
          <li>Western Pacific: 97Â million chronically infected</li>
          <li>African Region: 65Â million</li>
          <li>Southâ€‘East Asia: 61Â million</li>
          <li>Eastern Mediterranean: 15Â million</li>
          <li>European Region: 11Â million</li>
          <li>Americas: 5Â million</li>
        </ul>

        <h3>Transmission</h3>
        <p><strong>Highâ€‘endemic areas:</strong> HBV is most often transmitted from mother to child (perinatal) or through horizontal exposure to infected blood in early childhood. Chronic infection develops in ~95Â % of infants infected this way, versus <5Â % of adults.</p>
        <ul>
          <li>Needle sticks, tattoos, piercings</li>
          <li>Exposure to infected blood or body fluids (saliva, menstrual blood, vaginal secretions, semen)</li>
          <li>Reuse of contaminated needles/syringes in healthcare settings or among people who inject drugs</li>
          <li>Sexual transmission (higher risk in unvaccinated individuals with multiple partners)</li>
        </ul>
        <p>HBV can survive outside the body for at least 7Â days. Incubation: 30â€“180Â days; the virus becomes detectable 30â€“60Â days postâ€‘infection and may persist, leading to chronic hepatitisÂ B.</p>

        <h3>Symptoms</h3>
        <p>Most newly infected individuals are asymptomatic. Acute symptoms (lasting weeks) can include jaundice, dark urine, fatigue, nausea, vomiting, and abdominal pain. Severe acute hepatitis can lead to liver failure and death. Chronic hepatitisÂ B may progress to cirrhosis or liver cancer.</p>

        <h3>HBVâ€“HIV Coinfection</h3>
        <ul>
          <li>~1Â % of people with HBV (â‰ˆ2.7Â million) are also infected with HIV.</li>
          <li>Global HBV prevalence among people with HIV: 7.4Â %.</li>
          <li>WHO recommends HIV treatment for all diagnosed individuals; tenofovir in firstâ€‘line regimens is also active against HBV.</li>
        </ul>

        <h3>Diagnosis</h3>
        <p>HBV cannot be distinguished from other hepatitis viruses by symptoms alone; laboratory testing is essential. Blood tests determine acute vs. chronic infection and monitor liver damage. Liver fibrosis can be assessed by clinical exam, ultrasound, or elastography. All donated blood should be tested for HBV.</p>
        <ul>
          <li>2022: Only 13Â % of people with HBV knew their status; 3Â % (7Â million) were on treatment.</li>
          <li>Chronic HBV in children under 5 has dropped from â‰ˆ5Â % (preâ€‘vaccine era) to <1Â % in 2019.</li>
        </ul>
        <p><strong>Testing recommendations:</strong> In areas with >2Â % HBsAg prevalence, offer universal adult testing. Prioritize blood donors, pregnant women, and highâ€‘risk groups (migrants from endemic areas, close contacts, healthcare workers, people who inject drugs, prisoners, men who have sex with men, sex workers, people with HIV).</p>

        <h3>Treatment</h3>
        <p>No specific therapy exists for acute hepatitisÂ B; care focuses on comfort, hydration, and nutrition. Chronic HBV can be treated with oral antivirals such as tenofovir or entecavir, which slow cirrhosis, reduce liver cancer risk, and improve survival. Most patients require lifelong therapy. Updated WHO guidelines recommend treatment for >50Â % of chronic HBV cases, depending on context.</p>
        <p><strong>Liver cancer management:</strong> In lowâ€‘income settings, most patients present late and die within months. In highâ€‘income countries, earlier detection allows surgery, chemotherapy, or liver transplantation.</p>

        <h3>Prevention</h3>
        <ul>
          <li>Birth dose of HBV vaccine within 24Â hours, followed by 2â€“3 additional doses â‰¥4Â weeks apart.</li>
          <li>Booster doses generally unnecessary after the 3â€‘dose series; protection lasts â‰¥20Â years, likely lifelong.</li>
          <li>Antiviral therapy plus vaccination prevents motherâ€‘toâ€‘child transmission.</li>
          <li>Safer sex practices, avoiding needle sharing, proper hand hygiene, and vaccination of healthcare workers further reduce transmission.</li>
        </ul>

        <h3>WHO Action</h3>
        <p>The Global Health Sector Strategies on HIV, Viral Hepatitis, and STIs (2022â€“2030) aim to eliminate chronic HBV and HCV as public health threats by 2030, emphasizing prevention, testing, and treatment with a focus on highâ€‘risk populations and inequities. World Hepatitis Day 2023 adopted the theme "One Life, One Liver" to underscore liver health and the urgency of scaling up HBV elimination efforts.</p>
      </div>
    </section>

    <!-- Contact -->
    <section id="contact">
      <div class="container" style="max-width:800px">
        <h2>Contact Us</h2>
        <ul>
          <li><strong>Prof. GillesÂ Wandeler</strong> â€“ Head, Infectious Diseases, Bern University Hospital â€“ <a href="mailto:gilles.wandeler@unibe.ch">gilles.wandeler@unibe.ch</a></li>
          <li><strong>Prof. MoussaÂ Seydi</strong> â€“ Head, Infectious Diseases, CHNU Fann, Dakar â€“ <a href="mailto:seydi.moussa@gmail.com">seydi.moussa@gmail.com</a></li>
          <li><strong>Dr. AdriÃ Â RamirezÂ Mena</strong> â€“ Researcher in Epidemiology, University of Bern â€“ <a href="mailto:adri%C3%A0.ramirez@posteo.net">adriÃ .ramirez@posteo.net</a></li>
          <li><strong>BintouÂ Fall, MSc</strong> â€“ Biologist & Research Assistant, Infectious Diseases, CHNU Fann, Dakar â€“ <a href="mailto:bintoufall2298@gmail.com">bintoufall2298@gmail.com</a></li>
        </ul>
      </div>
    </section>
  </main>

  <!-- Chatbot floating button & window -->
  <button class="chat-btn" onclick="toggleChat()">ðŸ’¬</button>
  <div id="chatWin" class="chat-window">
    <div class="chat-header">SEN-B Bot</div>
    <div id="chatMsgs" class="chat-messages"></div>
    <div class="chat-input">
      <input id="chatInput" type="text" placeholder="Type your questionâ€¦">
      <button onclick="sendChat()">Send</button>
    </div>
  </div>

  <footer>
    &copy; 2025 SEN-B Project â€“ All rights reserved
  </footer>
</body>
</html>
